The clinical development of obinutuzumab for the treatment of follicular lymphoma

References

• HowladerNMortonLMFeuerEJBessonCEngelsEAContributions of subtypes of non-Hodgkin lymphoma to mortality trendsCancer Epidemiol Biomarkers Prev201625117417926472423
   PubMed Web of Science ®Google Scholar
• JaffeESThe 2008 WHO classification of lymphomas: implications for clinical practice and translational researchHematology Am Soc Hematol Educ Program200952353120008237
   PubMedGoogle Scholar
• van MeertenTHagenbeekACD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin’s lymphomaNeth J Med200967725125919687518
   PubMed Web of Science ®Google Scholar
• CraggMSMorganSMChanHTComplement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid raftsBlood200310131045105212393541
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324354457506951
   PubMed Web of Science ®Google Scholar
• HeroldMHaasASrockSRituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology StudyJ Clin Oncol200725151986199217420513
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood200510541417142315494430
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKSolal-CelignyPPhase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaJ Clin Oncol200826284579458618662969
   PubMed Web of Science ®Google Scholar
• SallesGMounierNde GuibertSRituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyBlood2008112134824483118799723
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• FlinnIWvan der JagtRKahlBSRandomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood2014123192944295224591201
   PubMed Web of Science ®Google Scholar
• FedericoMLuminariSDondiAR-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana LinfomiJ Clin Oncol201331121506151323530110
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• van MeertenTvan RijnRSHolSHagenbeekAEbelingSBComplement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicityClin Cancer Res200612134027403516818702
   PubMed Web of Science ®Google Scholar
• CzuczmanMSOlejniczakSGowdaAAcquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levelsClin Cancer Res20081451561157018316581
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJMayerJOfatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol201028101749175520194866
   PubMed Web of Science ®Google Scholar
• TeelingJLMackusWJWiegmanLJThe biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20J Immunol2006177136237116785532
   PubMed Web of Science ®Google Scholar
• HagenbeekAGadebergOJohnsonPFirst clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood2008111125486549518390837
   PubMed Web of Science ®Google Scholar
• CzuczmanMSFayadLDelwailVOfatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyBlood2012119163698370422389254
   PubMed Web of Science ®Google Scholar
• NiederfellnerGLammensAMundiglOEpitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesBlood2011118235836721444918
   PubMed Web of Science ®Google Scholar
• KleinCLammensASchäferWEpitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesMAbs201351223323211638
   PubMed Web of Science ®Google Scholar
• AlduaijWIvanovAHoneychurchJNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood2011117174519452921378274
   PubMed Web of Science ®Google Scholar
• HoneychurchJAlduaijWAzizyanMAntibody-induced non-apoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathwayBlood2012119153523353322354003
   PubMed Web of Science ®Google Scholar
• AshrafSQUmanaPMössnerEHumanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosisBr J Cancer2009101101758176819904275
   PubMed Web of Science ®Google Scholar
• MössnerEBrünkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood2010115224393440220194898
   PubMed Web of Science ®Google Scholar
• LiuSDChalouniCYoungJCJunttilaTTSliwkowskiMXLoweJBAfucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCCCancer Immunol Res20153217318325387893
   PubMed Web of Science ®Google Scholar
• HerterSHertingFMundiglOPreclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsMol Cancer Ther201312102031204223873847
   PubMed Web of Science ®Google Scholar
• DalleSReslanLde HortsTBPreclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Mol Cancer Ther201110117818521220500
   PubMed Web of Science ®Google Scholar
• DecaupEJeanCLaurentCAnti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D modelBlood Cancer J20133e13123933705
   PubMed Web of Science ®Google Scholar
• HertingFFriessTBaderSEnhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphomaLeuk Lymphoma20145592151216024304419
   PubMed Web of Science ®Google Scholar
• KernDJJamesBRBlackwellSGassnerCKleinCWeinerGJGA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentLeuk Lymphoma201354112500250523452151
   PubMed Web of Science ®Google Scholar
• CartronGHourcade-PotelleretFMorschhauserFRationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphomaHaematologica2016101222623426659915
   PubMed Web of Science ®Google Scholar
• SallesGMorschhauserFLamyTPhase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patientsBlood2012119225126513222431570
   PubMed Web of Science ®Google Scholar
• OguraMTobinaiKHatakeKPhase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphomaCancer Sci2013104110511023046388
   PubMed Web of Science ®Google Scholar
• SehnLHAssoulineSEStewartDAA phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesBlood2012119225118512522438256
   PubMed Web of Science ®Google Scholar
• SallesGAMorschhauserFSolal-CelignyPObinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol201331232920292623835715
   PubMed Web of Science ®Google Scholar
• SehnLHGoyAOffnerFCRandomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ Indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS studyJ Clin Oncol201533303467347426282650
   PubMed Web of Science ®Google Scholar
• RadfordJDaviesACartronGObinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)Blood201312271137114323843495
   PubMed Web of Science ®Google Scholar
• DyerMJGriggAPDíazMGObinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase IB GAUDI studyBlood2014124211743
   Web of Science ®Google Scholar
• GriggADyerMJDíazMGSafety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaHaematologica20162016152272
   Google Scholar
• SehnLHChuaNMayerJObinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLancet Oncol20161781081109327345636
   PubMed Web of Science ®Google Scholar
• ChesonBDTrněnýMBouabdallahKObinutuzumab plus bendamustine followed by obinutuzumab maintenance prolongs overall survival compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: updated results of the GADOLIN studyBlood20161282261527288518
   PubMed Web of Science ®Google Scholar
• MarcusREDaviesAJAndoKObinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized phase 3 GALLIUM studyBlood2016128226
   Web of Science ®Google Scholar
• FowlerNHDavisRERawalSSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialLancet Oncol201415121311131825439689
   PubMed Web of Science ®Google Scholar
• Lymphoma Academic Research OrganisationA phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (RELEVANCE) Available from: https://clinicaltrials.gov/ct2/show/NCT01650701. NLM identifier: NCT01650701Accessed March 27, 2017
   Google Scholar
• MorschhauserFSallesGLe GouillSA Phase IB study of obinutuzumab combined with lenalidomide for relapsed/refractory follicular B-cell lymphomaBlood2014124214458
   Web of Science ®Google Scholar
• Lymphoma Academic Research OrganisationStudy of obinutuzumab combined to lenalidomide for the treatment of relapsed/refractory follicular and aggressive B-cell lymphoma Available from: https://clini-caltrials.gov/ct2/show/NCT01582776. NLM identifier: NCT01582776Accessed March 27, 2017
   Google Scholar
• FowlerNPintoRMCheahCYA phase I study of lenalidomide plus a next generation anti-CD20 antibody, obinutuzumab, in relapsed indolent lymphomaBlood2015126232742
   Web of Science ®Google Scholar
• MD Anderson Cancer CenterStudy of obinutuzumab and lenalidomide in previously untreated subjects with follicular lymphoma Available from: https://clinicaltrials.gov/ct2/show/NCT02871219. NLM identifier: NCT02871219Accessed March 27, 2017
   Google Scholar
• CasuloCSanchoJMVan EygenKContempo: preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-δ,γ inhibitor, duvelisib, in combination with rituximab or obinutuzumabBlood2016128222979
   Web of Science ®Google Scholar
• University of MunichCombination of PCI-32765 with obinutuzumab in untreated follicular lymphoma Available from: https://clinicaltrials.gov/ct2/show/NCT02689869. NLM identifier: NCT02689869Accessed March 27, 2017
   Google Scholar
• WahlinBEAggarwalMMontes-MorenoSA unifying micro-environment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophagesClin Cancer Res201016263765020068089
   PubMed Web of Science ®Google Scholar
• YangZZGroteDMZiesmerSCXiuBNovakAJAnsellSMPD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalBlood Cancer J20155e28125700246
   PubMed Web of Science ®Google Scholar
• MyklebustJHIrishJMBrodyJHigh PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cellsBlood201312181367137623297127
   PubMed Web of Science ®Google Scholar
• WestinJRChuFZhangMSafety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialLancet Oncol2014151697724332512
   PubMed Web of Science ®Google Scholar
• TillBGParkSIPopplewellLLSafety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphomaBlood2015126235104
   Web of Science ®Google Scholar
• DavidsMSRobertsAWSeymourJFPhase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphomaJ Clin Oncol201735882683728095146
   PubMed Web of Science ®Google Scholar
• ZelenetzADSallesGAMasonKDResults of a phase IB study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphomaBlood201612822303228034871
   PubMed Web of Science ®Google Scholar
• Swiss Group for Clinical Cancer ResearchObinutuzumab in combination with venetoclax in previously untreated follicular lymphoma patients Available from: https://clinicaltrials.gov/ct2/show/NCT02877550. NLM identifier: NCT02877550Accessed March 27, 2017
   Google Scholar
• Ohio State University Comprehensive Cancer CenterObinutuzumab, venetoclax, and lenalidomide in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma Available from: https://clini-caltrials.gov/ct2/show/NCT02992522. NLM identifier: NCT02992522Accessed March 27, 2017
   Google Scholar
• PhillipsTBrunvandMChenAPolatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase IB/II studyBlood201612822622
   Web of Science ®Google Scholar
• HerreraAFMatasarMJAssoulineSPolatuzumab vedotin combined with bendamustine (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL): preliminary results of a phase IB/II dose-escalation studyBlood2016128224194
   Web of Science ®Google Scholar
• Hoffmann-La RocheA study of obinutuzumab, polatuzumab vedotin, and venetoclax in relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) Available from: https://clini-caltrials.gov/ct2/show/NCT02611323. NLM identifier: NCT02611323Accessed March 27, 2017
   Google Scholar
• GibianskyEGibianskyLCarlileDJJamoisCBuchheitVFreyNPopulation pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma and exposure-response in CLLCPT Pharmacometrics Syst Pharmacol20143e14425353187
   PubMedGoogle Scholar
• Gazyva ® (obinutuzumab) [package insert]San FranciscoGenentech2013 revised in 2016
   Google Scholar
• FreemanCLMorschhauserFSehnLCytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactionsBlood2015126242646264926447188
   PubMed Web of Science ®Google Scholar
• van der KolkLEGrillo-LopezAJBaarsJWHackCEvan OersMHComplement activation plays a key role in the side-effects of rituximab treatmentBr J Haematol2001115480781111843813
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol20011982153216411304767
   PubMed Web of Science ®Google Scholar
• ByrdJCWaselenkoJKManeatisTJRituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearanceJ Clin Oncol199917379179510071268
   PubMed Web of Science ®Google Scholar
• WinklerUJensenMManzkeOSchulzHDiehlVEngertACytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)Blood19999472217222410498591
   PubMed Web of Science ®Google Scholar
• DunleavyKTayKWilsonWHRituximab-associated neutropeniaSemin Hematol201047218018620350665
   PubMed Web of Science ®Google Scholar
• TrotmanJLuminariSBoussettaSPrognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studiesLancet Haematol201411e17e2727030064
   PubMed Web of Science ®Google Scholar